Related Experiment Videos
[The use of instenon in children with minimal brain dysfunction]
Insights
Instenon effectively treated minimal brain dysfunction (MBD) in children, improving behavior, school performance, and cognitive functions. This nootropic medication showed significant benefits compared to a placebo in a controlled study.
Area of Science:
- Pediatric Neurology
- Neuropsychology
- Pharmacology
Context:
- Minimal brain dysfunction (MBD) is a common childhood neuropsychic disorder.
- MBD presents with diverse symptoms including motor, speech, learning, and attention deficits.
- Current treatment options for MBD require further investigation for efficacy.
Purpose:
- To evaluate the efficacy of the nootropic medication Instenon in treating children with MBD.
- To compare the effects of Instenon with a placebo (polyvitamin) in a controlled study.
- To assess improvements in behavioral, academic, and cognitive parameters.
Summary:
- A study involving 59 children (aged 4-12) with MBD assessed Instenon's efficacy over one month.
- Instenon treatment resulted in positive effects in 71% of cases, versus 15% in the control group.
- Improvements were observed in behavior, school marks, motor skills, attention, memory, and executive functions.
Impact:
- Instenon demonstrated significant therapeutic benefits for children diagnosed with minimal brain dysfunction.
- The study highlights Instenon as a potentially valuable treatment option for MBD symptoms.
- Minimal side effects were reported when Instenon was administered according to the prescribed regimen.
Abstract:
Minimal brain dysfunction (MBD) represents the most common type of neuropsychic disorders in childhood. Resulting in focal damages, underdevelopment and dysfunction of one or another cortical regions of brain hemispheres, MBD manifested in children as movement and speech disorders, dysgraphy, dyslexia, dyscalculia and attention deficit hyperactivity disorder. In the open controlled study, an efficacy of the complex nootropic medication "Instenon" was evaluated in the treatment of 59 MBD patients, aged 4-12 years. Control group included 27 children with MBD assigned to low polyvitamin (Sana Sol) doses. The treatment duration was 1 month. Before and after treatment, children with MBD underwent complex examination, which included parent's interviewing using structured questionnaire, general examination, with detailed analysis of complaints, neurological status investigation and psychological study. In the children taken instenon, distinct positive effect has been achieved in 71% of the cases, in control group--in 15%. Positive effect emerged in improvement of behavior characteristics, better school marks, movement, attention and memory indices, functions of psychic activity, organization, programming and control. When strictly keeping a scheme prescribed (gradual dose increase, drug taking in morning and day time), a risk for unfavorable side effects is minimal.